市場調查報告書
商品編碼
1541630
2024-2032 年按應用(糖尿病、肥胖、心血管疾病、中樞神經系統疾病、呼吸道疾病、戒菸等)、最終用途(患者、提供者、付款人、雇主等)和地區分類的數位治療市場報告Digital Therapeutics Market Report by Application (Diabetes, Obesity, CVD, CNS Disease, Respiratory Diseases, Smoking Cessation, and Others), End Use (Patients, Providers, Payers, Employers, and Others), and Region 2024-2032 |
2023年全球IMARC Group治療市場規模達60億美元。對數位行為監測治療的需求不斷成長、慢性病盛行率不斷上升以及大眾對個人健康和健身意識的不斷提高是推動市場的關鍵因素之一。
智慧型手機和平板電腦使用量的增加推動市場成長
對智慧型手機和平板電腦的日益依賴,加上不同的醫療保健應用程式,正在推動數位治療市場的成長。智慧型手機和基於平板電腦的醫療保健應用程式具有降低用藥錯誤率、促進預防性護理和更準確的人員配置等眾多優勢。個人科技設備在醫療保健領域的使用不斷增加,刺激了對數位療法 (DTx) 治療的需求。 DTx 正在增強患者獲得治療的安全性和有效性,以不同語言呈現訊息,提供有關疾病和治療的相關資訊,並擴大醫生護理患者的能力。此外,它是一種先進的護理服務模式,可以在家中輕鬆實施,並消除與傳統療法相關的任何恥辱。
報告涵蓋了市場結構、主要參與者的市場佔有率、參與者定位、最佳制勝策略、競爭儀表板和公司評估象限等競爭分析。此外,也提供了所有主要公司的詳細資料。市場結構適度分散,有大量全球和區域參與者。此外,由於研發(R&D)創新和併購(M&A)數量的增加,該市場的競爭環境正在加劇。由於市場結構分散、產品差異化和轉換成本較低,數位治療行業的新進入者數量適中。此外,行動醫療開發商數量的不斷增加也加劇了新進入者的巨大威脅。然而,先進技術的專利要求和高成本以及嚴格的監管程序減少了新進入者的威脅。
什麼是數位治療?
數位療法 (DTx) 是一種由高品質軟體程式驅動的實證治療介入措施,用於預防、管理或治療醫學病症或疾病。它是軟體即醫療設備 (SaMD) 的一種形式,依靠軟體介入來改變患者的行為並幫助治療他們的病情。 DTx 是一類快速且新興的療法,利用軟體獨立治療疾病或最佳化治療。它有助於預防和管理多種疾病和病症,如2 型糖尿病、充血性心臟衰竭、肥胖、阿茲海默症、失智症、氣喘、藥物濫用、注意力不足過動症(ADHD)、高血壓、焦慮、憂鬱、和其他幾個。 DTx 還有助於提高患者用藥依從性,並支持醫療保健專業人員 (HCP) 以數位方式管理患者和業務。
COVID-19大流行的到來可謂醫療保健產業的分水嶺。它極大地改變了醫療保健提供的方式,同時暴露了世界各國政府在充分應對全球醫療保健緊急情況方面缺乏準備。第一線衛生工作者參與管理 COVID-19 患者,但患有其他健康問題的患者,尤其是慢性健康問題的患者,由於推遲或避免去診所就診,因此遇到了困難。此外,由於患有合併症(尤其是肥胖、心臟併發症和糖尿病)的患者中的 COVID-19 結局比沒有合併症的患者更差,因此要求這些患者額外保持警惕。這場大流行也帶來了相當一部分精神健康障礙,包括憂鬱、焦慮和戒斷,由於缺乏面對面的就診,這些疾病的管理是一個挑戰。這些相互關聯的事件促使醫療保健提供者尋求數位健康解決方案來應對健康危機。在 COVID-19 爆發期間,數位醫療技術的採用出現了積極的趨勢,提高了醫療保健營運和服務提供的效率和有效性。疫情發生後,DTx應用在各領域的採用加速了數倍。此外,COVID-19 大流行透過改變患者參與度和整合整個醫療保健領域的資料,增加了虛擬和家庭護理技術的採用。
目前,2 型糖尿病患者對 DTx 的需求不斷增加,以控制疾病並使他們能夠使用支援物聯網 (IoT) 的胰島素幫浦和其他健康監測系統。再加上對數位行為監測治療的需求不斷成長,以確保藥物依從性和健康生活方式的改變,這是支持市場成長的關鍵因素之一。此外,與傳統治療相比,擴大使用 DTx 來減少更多後續檢查和復發的需要,這提供了良好的市場前景。此外,心臟病、中風、癌症、肥胖和關節炎等慢性疾病的盛行率也在增加。再加上大眾對個人健康和健身意識的不斷提高,正在推動市場的成長。此外,對 DTx 的需求不斷成長,以幫助醫生管理患者對醫療方案的依從性,並建立一個綜合的健康生態系統,使資料能夠在付款人、提供者和藥房等不同利益相關者之間無縫傳輸,這正在推動市場的成長。
The global digital therapeutics market size reached US$ 6.0 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 26.8 Billion by 2032, exhibiting a growth rate (CAGR) of 17.5% during 2024-2032. The growing demand for digital behavior-monitoring treatment, increasing prevalence of chronic diseases, and rising awareness among the masses about personal health and fitness represent one of the key factors driving the market.
Increasing Usage of Smartphones and Tablets Propelling Market Growth
The rising reliance on smartphones and tablets, coupled with different healthcare apps, is propelling the growth of the digital therapeutics market. Smartphones and tablet-based healthcare apps have numerous advantages over the lower rate of medication errors, facilitating preventive care, and more accurate staffing. The increasing utilization of personal technological devices in healthcare is catalyzing the demand for digital therapeutics (DTx) treatments. DTx is enhancing patient access to the safety and effectiveness of treatments, presenting information in different languages, providing relevant information about diseases and treatments, and expanding the ability of physicians to care for patients. Furthermore, it is an advanced mode of care delivery, which can be easily implemented at home and eliminates any stigma associated with traditional therapies.
Competitive analysis such as market structure, market share by key players, player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided. The market structure is moderately fragmented with the presence of a large number of global and regional players. Moreover, the competitive environment in this market is intensifying due to the increasing number of research and development (R&D) innovations and mergers and acquisitions (M&A). The volume of new entrants is moderate in the digital therapeutics industry due to the fragmented market structure and low product differentiation and switching cost. In addition, the growing number of mhealth developers is contributing to the high threat of new entrants. However, the requirement of patents and high costs of advanced technologies along with stringent regulatory procedures, decreases the threat from new entrants.
What are Digital Therapeutics?
Digital therapeutics (DTx) is an evidence-based therapeutic intervention driven by high-quality software programs to prevent, manage, or treat a medical disorder or disease. It is a form of a software-as-a-medical device (SaMD) that relies on software interventions to bring about behavioral changes in patients and help treat their conditions. DTx is a fast-emerging class of therapies that utilizes software to treat disease as a standalone or for treatment optimization. It assists in preventing and managing a wide variety of diseases and conditions, such as type 2 diabetes, congestive heart failure, obesity, Alzheimer's disease, dementia, asthma, substance abuse, attention deficit hyperactivity disorder (ADHD), hypertension, anxiety, depression, and several others. DTx also aids in improving patient medication adherence and supporting healthcare professionals (HCPs) to manage their patients and businesses digitally.
The arrival of the COVID-19 pandemic can be described as a watershed moment for the healthcare industry. It changed the manner of healthcare delivery dramatically while exposing the lack of preparedness on the part of governments worldwide to adequately tackle a global healthcare emergency. Frontline health workers were involved in managing COVID-19 patients, but patients with other health conditions, especially chronic health conditions, experienced difficulties as their in-clinic visits were postponed or avoided. Moreover, as the outcomes of COVID-19 among patients with comorbidities, especially obesity, heart complications, and diabetes, were worse than those without, these patients were asked to be additionally vigilant. The pandemic also brought a fair share of mental health disorders, including depression, anxiety, and withdrawals, and their management was a challenge due to the lack of face-to-face visits. These interconnected events have made healthcare providers look out for digital health solutions to tackle health crisis. There was a positive trend observed during the COVID-19 outbreak in relation to the adoption of digital health technologies, which increased the efficiency and effectiveness of healthcare operations and service delivery. After the pandemic started, the adoption of DTx applications in various fields accelerated many folds. Additionally, the COVID-19 pandemic increased the adoption of virtual and home care technologies by transforming patient engagement and integrating data across the healthcare landscape.
At present, there is a rise in the demand for DTx among type 2 diabetes patients to manage the disease and enable them to use the internet of things (IoT)-enabled insulin pumps and other health monitoring systems. This, along with the increasing demand for digital behavior-monitoring treatment to ensure medication adherence and healthy lifestyle changes, represents one of the key factors supporting the growth of the market. In addition, the growing utilization of DTx to reduce the need for more follow-up checkups and relapses compared to traditional treatments is offering a favorable market outlook. Moreover, there is an increase in the prevalence of chronic diseases, such as heart disease, stroke, cancer, obesity, and arthritis. This, coupled with the rising awareness among the masses about personal health and fitness, is propelling the growth of the market. Additionally, the escalating demand for DTx to help doctors manage patient adherence to medical regimens and build an integrated health ecosystem that can enable the seamless transfer of data between different stakeholders, such as payers, providers, and pharmacies, is bolstering the growth of the market.
IMARC Group provides an analysis of the key trends in each sub-segment of the global digital therapeutics market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on application and end use.
Diabetes
Obesity
CVD
CNS Disease
Respiratory Diseases
Smoking Cessation
Others
The report has provided a detailed breakup and analysis of the digital therapeutics market based on the application. This includes diabetes, obesity, CVD, CNS disease, respiratory diseases, smoking cessation, and others. According to the report, diabetes represented the largest segment due to the rising prevalence of diabetes, along with the high risk of associated conditions, such as cardiac arrests, kidney failure, and blindness, in diabetic patients. Moreover, the growing integration of DTx with numerous medical devices, such as insulin pumps, glucose blood meters, and wearable gadgets, is positively influencing the market.
Patients
Providers
Payers
Employers
Others
A detailed breakup and analysis of the digital therapeutics market based on the end use has also been provided in the report. This includes patients, providers, payers, employers, and others. According to the report, patients accounted for the largest market share due to the rising adoption of DTx among patients for numerous associated benefits pertaining to elective health management at an affordable cost. In addition, the increasing consumer inclination towards patient management systems for improving retention and compliance with post hospitalization follow-up visits is catalyzing the demand for DTx.
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America (the United States and Canada) was the largest market for digital therapeutics. Some of the factors driving the North America digital therapeutics market included the growing geriatric population, continuous upgradations in drug approval processes by the Food and Drug Administration (FDA), rising awareness about the benefits of DTx, etc. In addition, the growing utilization of DTx as a standalone therapy or in conjunction with medications, devices, and other therapies to optimize patient care and healthcare outcomes is offering a favorable market outlook.
2Morrow Inc.
Canary Health Inc.
Click Therapeutics Inc.
Mango Health Inc. (TrialCard Incorporated)
Noom Health Inc.
Omada Health Inc.
Pear Therapeutics, Inc.
Propeller Health (ResMed)
Teladoc Health Inc.
Voluntis Inc.
WellDoc Inc.
Please note that this only represents a partial list of companies, and the complete list has been provided in the report.